Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.

A small pre-treatment 'priming' dose of cyclophosphamide will reduce gut damage due to high dose i.v. melphalan in mice and sheep but efforts to demonstrate this effect in man have been hampered by difficulty in the measurement of gut damage. We have evaluated the 51CR EDTA absorption test...

Descripción completa

Detalles Bibliográficos
Autores principales: Selby, P. J., Lopes, N., Mundy, J., Crofts, M., Millar, J. L., McElwain, T. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001721/
https://www.ncbi.nlm.nih.gov/pubmed/3111515
_version_ 1782135662307180544
author Selby, P. J.
Lopes, N.
Mundy, J.
Crofts, M.
Millar, J. L.
McElwain, T. J.
author_facet Selby, P. J.
Lopes, N.
Mundy, J.
Crofts, M.
Millar, J. L.
McElwain, T. J.
author_sort Selby, P. J.
collection PubMed
description A small pre-treatment 'priming' dose of cyclophosphamide will reduce gut damage due to high dose i.v. melphalan in mice and sheep but efforts to demonstrate this effect in man have been hampered by difficulty in the measurement of gut damage. We have evaluated the 51CR EDTA absorption test, a new method for measuring intestinal permeability, as a means of assessing damage due to high dose melphalan. The test was reliable, with a narrow normal range, easy to use and well tolerated. It detected an increase in intestinal permeability after high dose melphalan with a maximum occurring between 9 and 15 days after treatment and subsequently returning to normal. It was shown in 19 patients that a pre-treatment dose of cyclophosphamide was capable of significantly reducing the abnormalities in intestinal permeability which resulted from high dose melphalan.
format Text
id pubmed-2001721
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20017212009-09-10 Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy. Selby, P. J. Lopes, N. Mundy, J. Crofts, M. Millar, J. L. McElwain, T. J. Br J Cancer Research Article A small pre-treatment 'priming' dose of cyclophosphamide will reduce gut damage due to high dose i.v. melphalan in mice and sheep but efforts to demonstrate this effect in man have been hampered by difficulty in the measurement of gut damage. We have evaluated the 51CR EDTA absorption test, a new method for measuring intestinal permeability, as a means of assessing damage due to high dose melphalan. The test was reliable, with a narrow normal range, easy to use and well tolerated. It detected an increase in intestinal permeability after high dose melphalan with a maximum occurring between 9 and 15 days after treatment and subsequently returning to normal. It was shown in 19 patients that a pre-treatment dose of cyclophosphamide was capable of significantly reducing the abnormalities in intestinal permeability which resulted from high dose melphalan. Nature Publishing Group 1987-05 /pmc/articles/PMC2001721/ /pubmed/3111515 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Selby, P. J.
Lopes, N.
Mundy, J.
Crofts, M.
Millar, J. L.
McElwain, T. J.
Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
title Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
title_full Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
title_fullStr Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
title_full_unstemmed Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
title_short Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
title_sort cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001721/
https://www.ncbi.nlm.nih.gov/pubmed/3111515
work_keys_str_mv AT selbypj cyclophosphamideprimingreducesintestinaldamageinmanfollowinghighdosemelphalanchemotherapy
AT lopesn cyclophosphamideprimingreducesintestinaldamageinmanfollowinghighdosemelphalanchemotherapy
AT mundyj cyclophosphamideprimingreducesintestinaldamageinmanfollowinghighdosemelphalanchemotherapy
AT croftsm cyclophosphamideprimingreducesintestinaldamageinmanfollowinghighdosemelphalanchemotherapy
AT millarjl cyclophosphamideprimingreducesintestinaldamageinmanfollowinghighdosemelphalanchemotherapy
AT mcelwaintj cyclophosphamideprimingreducesintestinaldamageinmanfollowinghighdosemelphalanchemotherapy

Ejemplares similares